Loading company
4D Molecular Therapeutics, Inc.
FDMT · Nasdaq · ·
Next earnings: November 9, 2026
$14.50-0.6%Sep 29 close
- 1M
- -1.2%
- 6M
- +69.2%
- 1Y
- +66.9%
- 5Y
- -48.1%
FDMT · Nasdaq · ·
Next earnings: November 9, 2026
$14.50-0.6%Sep 29 close
4D Molecular Therapeutics, Inc. is scheduled to report next on November 9, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $3.8M | $15K | +25,106.67% |
| Profit | -$72.9M | -$54.7M | -33.44% |
| Profit per share | -$1.04 | -$0.98 | -6.12% |
| Free Cash Flow | $28.6M | -$46.8M | +161.14% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“The second quarter of 2026 reflected continued strong execution across 4DMT, including completion of enrollment for 4FRONT-2, presenting positive long-term PRISM data and strengthening our financial flexibility through securing a strategic credit facility with Hercules,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
The quote and the company description come from 4D Molecular Therapeutics, Inc.’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
4D Molecular Therapeutics, Inc. has no earnings call transcript available.